Literature DB >> 36035009

Imaging for guiding a more tailored approach in rectal cancer patients.

Gaya Spolverato1, Filippo Crimì2, Salvatore Pucciarelli1.   

Abstract

Entities:  

Year:  2022        PMID: 36035009      PMCID: PMC9403946          DOI: 10.21037/atm-22-3498

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN: 2305-5839


× No keyword cloud information.
We read with great interest the paper by Chen et al. (1) that demonstrated the usefulness of Three-dimensional endorectal ultrasound (3D-ERUS) in rectal cancer evaluation after preoperative chemoradiotherapy (pCRT). The authors showed how the volume reduction of the rectal mass after pCRT allows the identification of good [tumor regression grade (TRG) 0 or 1] and complete responders (TRG 0) to neoadjuvant treatment with a high accuracy. The finding that the reduction of the volume of the rectal lesion is related to the response to pCRT is not new, but has mainly been detected in staging and restaging examinations performed with CT and MRI (2-4) and not with 3D-ERUS. These results are of interest since ERUS can be and additional tool that could be added to the standard restaging system mainly based on endoscopy and MRI, since it is a not expensive and radiation/contrast free imaging tool that could be easily introduced in the restaging work-flow of rectal cancer patients. Moreover, this finding is of outmost importance since the paradigm of rectal cancer treatment is progressively moving towards rectum sparing approaches especially among patients achieving complete response after pCRT (5,6). In the last years, the clinical interest towards rectum sparing approaches such as transanal local excision (LE) and watch and wait approaches has increased, since they proved to spare morbidity of total mesorectal excision (TME) while providing acceptable oncological outcomes in selected patients (5,6). The key question in these approaches is how accurate can be the prediction of pathological response among clinical complete responders, since, the more accurate is the restaging the more tailored can be the treatment of each patient affected by rectal cancer. Several efforts have been made to compare different techniques in predicting complete pathological response (7,8). Previous studies can be divided in 2 groups. First, the application of texture analysis on the classical radiological images of restaging (8-11); second, the use of innovative imaging techniques and their application to correlate complete clinical response with complete pathological response (12-15). The texture analysis showed promising results. This technique can extract a large amount of data that cannot be identified nor measured visually by the eye of the radiologists. The quantification and precise measurements of the normally qualitative evaluated parameters of imaging data has been demonstrated to be useful in rectal cancer (8-11). In the normal clinical setting on MR images the development of fibrosis after pCRT inside the rectal lesion is identified as a low signal in T2-wieghted sequences and a low signal on high b values diffusion weighted imaging (DWI) sequences (16). Thus, the pixel-by-pixel analysis performed by texture analysis can easily differentiate the presence of small foci of tumor cells in the lesion compared to the qualitative evaluation of the radiologist. Among the new techniques, PET/MRI (14) showed the most promising results. With this technique it is possible to combine precise anatomical and morphological data obtained by MR sequences and functional data deriving from MR sequences (i.e., DWI sequences) and PET images. In a recent systematic review 18F-FDG PET/MRI showed a better accuracy in T and N staging compared to PET/CT or MRI, confirming a role of this technique in selecting patients that can be managed with a rectum sparing approach (14). Both texture analysis using PET and MR images and innovative techniques can be used together to further improve the imaging accuracy (17,18). In the ongoing trials on rectum sparing approaches the clinical complete response is evaluated with endoscopy and digital rectal examination while MRI is the reference standard tool to exclude loco-regional nodal metastases (5,6). The future could include a multimodal imaging evaluation for T and N restaging, including both ERUS and MRI evaluation, with subsequent texture analysis of the images, aiming to obtain the most accurate assessment of the disease, while sparing contrast media or exposure to radiation. The article’s supplementary files as
  18 in total

Review 1.  MR Imaging Texture Analysis in the Abdomen and Pelvis.

Authors:  John V Thomas; Asser M Abou Elkassem; Balaji Ganeshan; Andrew D Smith
Journal:  Magn Reson Imaging Clin N Am       Date:  2020-06-06       Impact factor: 2.266

2.  Rectal sparing approach after preoperative radio- and/or chemotherapy (RESARCH) in patients with rectal cancer: a multicentre observational study.

Authors:  A Barina; A De Paoli; P Delrio; M Guerrieri; A Muratore; F Bianco; D Vespa; C Asteria; E Morpurgo; A Restivo; C Coco; U Pace; C Belluco; C Aschele; S Lonardi; V Valentini; G Mantello; I Maretto; P Del Bianco; A Perin; S Pucciarelli
Journal:  Tech Coloproctol       Date:  2017-07-28       Impact factor: 3.781

3.  18F-FDG PET/MRI for Rectal Cancer TNM Restaging After Preoperative Chemoradiotherapy: Initial Experience.

Authors:  Filippo Crimì; Gaya Spolverato; Carmelo Lacognata; Marco Garieri; Diego Cecchin; Emanuele D Urso; Pietro Zucchetta; Salvatore Pucciarelli; Fabio Pomerri
Journal:  Dis Colon Rectum       Date:  2020-03       Impact factor: 4.585

4.  MRI tumor volume reduction rate vs tumor regression grade in the pre-operative re-staging of locally advanced rectal cancer after chemo-radiotherapy.

Authors:  Emanuele Neri; Elisa Guidi; Francesca Pancrazi; Maura Castagna; Elisa Castelluccio; Riccardo Balestri; Piero Buccianti; Luca Masi; Alfredo Falcone; Bruno Manfredi; Lorenzo Faggioni; Carlo Bartolozzi
Journal:  Eur J Radiol       Date:  2015-08-20       Impact factor: 3.528

5.  Predicting locally advanced rectal cancer response to neoadjuvant therapy with 18F-FDG PET and MRI radiomics features.

Authors:  V Giannini; S Mazzetti; I Bertotto; C Chiarenza; S Cauda; E Delmastro; C Bracco; A Di Dia; F Leone; E Medico; A Pisacane; D Ribero; M Stasi; D Regge
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-01-13       Impact factor: 9.236

Review 6.  Diffusion weighted imaging and diffusion kurtosis imaging in abdominal oncological setting: why and when.

Authors:  Vincenza Granata; Roberta Fusco; Andrea Belli; Ginevra Danti; Eleonora Bicci; Carmen Cutolo; Antonella Petrillo; Francesco Izzo
Journal:  Infect Agent Cancer       Date:  2022-06-09       Impact factor: 3.698

7.  Comparison between CT volume measurement and histopathological assessment of response to neoadjuvant therapy in rectal cancer.

Authors:  Fabio Pomerri; Salvatore Pucciarelli; Gisella Gennaro; Isacco Maretto; Donato Nitti; Pier Carlo Muzzio
Journal:  Eur J Radiol       Date:  2012-08-16       Impact factor: 3.528

8.  Morphologic predictors of pathological complete response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer.

Authors:  Chongda Zhang; Feng Ye; Yuan Liu; Han Ouyang; Xinming Zhao; Hongmei Zhang
Journal:  Oncotarget       Date:  2017-12-19

9.  18F-FDG-PET/MRI texture analysis in rectal cancer after neoadjuvant chemoradiotherapy.

Authors:  Giulia Capelli; Cristina Campi; Quoc Riccardo Bao; Francesco Morra; Carmelo Lacognata; Pietro Zucchetta; Diego Cecchin; Salvatore Pucciarelli; Gaya Spolverato; Filippo Crimì
Journal:  Nucl Med Commun       Date:  2022-04-26       Impact factor: 1.698

10.  The predictive value of tumor volume reduction ratio on three-dimensional endorectal ultrasound for tumor response to chemoradiotherapy for locally advanced rectal cancer.

Authors:  Limei Chen; Xiaoyin Liu; Wenjing Zhang; Si Qin; Yimin Wang; Jing Lin; Qiu Chen; Guangjian Liu
Journal:  Ann Transl Med       Date:  2022-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.